UOC
AURA icon

UBS O'Connor’s Aura Biosciences AURA Stock Holding History

UBS O'Connor’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-151,108
Closed -$885K – 381
2025
Q1 		$885K Buy
151,108
+14,592
+11% +$110K 0.02% 196
2024
Q4 		$1.12M Buy
136,516
+29,618
+28% +$279K 0.03% 219
2024
Q3 		$952K Buy
106,898
+16,279
+18% +$140K 0.02% 282
2024
Q2 		$685K Buy
90,619
+23,294
+35% +$171K 0.02% 345
2024
Q1 		$529K Sell
67,325
-22,675
-25% -$188K 0.02% 331
2023
Q4 		$797K Buy
90,000
+46,000
+105% +$390K 0.03% 300
2023
Q3 		$395K Hold
44,000
– – 0.01% 418
2023
Q2 		$543K Buy
+44,000
New +$470K 0.01% 439
2022
Q4 		– Sell
-12,430
Closed -$225K – 760
2022
Q3 		$225K Sell
12,430
-78,109
-86% -$1.18M ﹤0.01% 842
2022
Q2 		$1.28M Buy
90,539
+41,539
+85% +$687K 0.01% 735
2022
Q1 		$1.08M Buy
+49,000
New +$933K 0.01% 685

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

UBS O'Connor's AURA Position: Q2 2025 in Review

UBS O'Connor sold out of Aura Biosciences (AURA) in Q2 2025, closing a stake of 151,108 shares — an estimated $885K sold.

UBS O'Connor first reported a position in AURA in Q1 2022 and held it in 11 quarters. The position peaked at $1.28M in Q2 2022. 104 funds tracked by Wall St. Rank hold AURA as of Q2 2025.

  • UBS O'Connor reported no remaining Aura Biosciences position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 151,108 Aura Biosciences shares in Q2 2025, an estimated $885K.
  • UBS O'Connor first reported a position in Aura Biosciences in Q1 2022 and held it in 11 quarters.
  • UBS O'Connor's Aura Biosciences position peaked at $1.28M in Q2 2022.
  • 104 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.